Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1040
Name chronic lymphocytic leukemia
Definition A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ATR over exp Ceralasertib chronic lymphocytic leukemia predicted - sensitive detail...
TP53 mutant Duvelisib chronic lymphocytic leukemia predicted - sensitive detail...
TP53 inact mut AZD6482 chronic lymphocytic leukemia predicted - sensitive detail...
ATM loss AZD6482 chronic lymphocytic leukemia sensitive detail...
TP53 inact mut Ceralasertib + Ibrutinib chronic lymphocytic leukemia sensitive detail...
ATM loss Ceralasertib + Ibrutinib chronic lymphocytic leukemia sensitive detail...
ATM inact mut Olaparib chronic lymphocytic leukemia sensitive detail...
TP53 mutant Ibrutinib + Venetoclax chronic lymphocytic leukemia predicted - sensitive detail...
TP53 mutant CG-806 chronic lymphocytic leukemia predicted - sensitive detail...
BRAF K601N PLX8394 chronic lymphocytic leukemia sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00577278 Phase II Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00829647 Phase Ib/II Dasatinib + Lenalidomide A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia Withdrawn 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT00881920 Phase I CAR.k.28 cells Cyclophosphamide + Fludarabine Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) Recruiting USA 0
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting USA 16
NCT01087294 Phase I Anti-CD19 CAR T cells Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT01125176 Phase II Lenalidomide + Rituximab + Thalidomide Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL Completed USA 0
NCT01173679 Phase II Dasatinib + Fludarabine + Rituximab Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Terminated USA 0
NCT01193842 Phase Ib/II Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01296932 Phase I BI 836826 BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed 3
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA 3
NCT01441882 Phase II Dasatinib A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity Completed USA 0
NCT01459211 Phase II Dexamethasone Lenalidomide Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) Completed 1
NCT01532700 Phase II Afuresertib + Ofatumumab An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) Completed CAN 0
NCT01556776 Phase III Lenalidomide A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Completed 1
NCT01604031 Phase Ib/II Lenalidomide Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Terminated USA 0
NCT01638533 Phase I Romidepsin Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Active, not recruiting USA | CAN 0
NCT01644253 Phase I Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Bendamustine + Otlertuzumab Phase 1b Safety and Efficacy Study of TRU-016 Terminated USA 0
NCT01660451 Phase II Copanlisib Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas Active, not recruiting USA | CAN 23
NCT01671904 Phase I Bendamustine + Obinutuzumab + Venetoclax Bendamustine + Rituximab + Venetoclax A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia Completed USA 2
NCT01685892 Phase I Obinutuzumab + Venetoclax A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia Completed USA 1
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA 5
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA 18
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | CAN 13
NCT01750567 Phase II Metformin A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL Unknown status USA 0
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated USA | CAN 0
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation USA | CAN 27
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01849276 Phase I Cytarabine + Metformin Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Terminated USA 0
NCT01853631 Phase I Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) Recruiting USA 0
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed USA 0
NCT01889186 Phase II Venetoclax A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion Completed USA | CAN 5
NCT01905813 Phase I Dezapelisib + Itacitinib Dezapelisib Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT01980875 Phase III Idelalisib + Obinutuzumab Chlorambucil + Obinutuzumab Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Terminated USA | CAN 6
NCT01980888 Phase III Bendamustine + Idelalisib + Rituximab Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Terminated USA | CAN 11
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA 3
NCT02004522 Phase III Duvelisib Ofatumumab A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Active, not recruiting USA 10
NCT02005289 Phase II Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Active, not recruiting USA 0
NCT02005471 Phase III Venetoclax Bendamustine Rituximab A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting USA | CAN 18
NCT02015208 Phase Ib/II Ruxolitinib Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia Completed CAN 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Completed USA 0
NCT02044822 Phase II Idelalisib + Rituximab Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Terminated USA 13
NCT02049515 Phase III Ofatumumab Duvelisib A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 Completed USA 10
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA | CAN 0
NCT02100423 Phase II Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed USA 0
NCT02100852 Phase I Chlorambucil + Obinutuzumab + Umbralisib TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) Completed USA 0
NCT02131584 Phase II Ruxolitinib Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA 0
NCT02135133 Phase II Idelalisib + Ofatumumab A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Active, not recruiting USA 0
NCT02141282 Phase II Venetoclax A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy Active, not recruiting USA 0
NCT02158091 Phase Ib/II Cyclophosphamide + Fludarabine + Rituximab Duvelisib A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL Active, not recruiting USA 0
NCT02160015 Phase I Ibrutinib + Lenalidomide + Rituximab Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02200848 Phase I Ibrutinib + Lenalidomide + Rituximab Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL Terminated USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02222688 Phase I Cirmtuzumab UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Completed USA 0
NCT02242942 Phase III Chlorambucil + Obinutuzumab Obinutuzumab + Venetoclax A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA | CAN 19
NCT02249429 Phase Ib/II PQR309 Open-Label, Non Randomized Phase 2 Study With Safety Run-In Completed USA 5
NCT02251548 Phase II Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02268851 Phase I Ibrutinib + Umbralisib A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Active, not recruiting USA 0
NCT02285244 Phase II Sotrastaurin Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation Withdrawn 0
NCT02292225 Phase I Duvelisib + Obinutuzumab IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi Terminated USA | CAN 0
NCT02296918 Phase I Acalabrutinib + Obinutuzumab ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL Active, not recruiting USA 0
NCT02301156 Phase III Ibrutinib + Ublituximab Ibrutinib Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed USA 0
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Suspended USA 0
NCT02315768 Phase Ib/II Ibrutinib + Obinutuzumab Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Active, not recruiting USA 0
NCT02319369 Phase I Milademetan Tosylate Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Terminated USA 0
NCT02332980 Phase II Pembrolizumab A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02340780 Phase II Buparlisib Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia Completed CAN 0
NCT02361346 Phase Ib/II MT-3724 Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) Terminated USA | CAN 8
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Active, not recruiting 10
NCT02420912 Phase II Ibrutinib + Nivolumab Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA 0
NCT02427451 Phase Ib/II Ibrutinib + Obinutuzumab + Venetoclax Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated USA 4
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA 2
NCT02475681 Phase III Acalabrutinib Chlorambucil Obinutuzumab Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL Unknown status USA | CAN 16
NCT02477696 Phase III Acalabrutinib Ibrutinib Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia Active, not recruiting USA 14
NCT02514083 Phase II Fludarabine + Ibrutinib A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL Active, not recruiting USA 0
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Completed USA 0
NCT02535286 Phase Ib/II Pembrolizumab + Ublituximab + Umbralisib Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL Active, not recruiting USA 0
NCT02537613 Phase I Ibrutinib + Obinutuzumab A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02538614 Phase Ib/II BI 836826 + Idelalisib Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia Terminated USA 0
NCT02557516 Phase Ib/II Ibrutinib + Monalizumab Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia Terminated USA 0
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Completed USA 0
NCT02611908 Phase I Ibrutinib + Obinutuzumab Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. Withdrawn 0
NCT02612311 Phase III Ublituximab Chlorambucil + Obinutuzumab Umbralisib Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 6
NCT02639910 Phase II Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Active, not recruiting USA 5
NCT02649387 Phase II Ibrutinib Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT) Active, not recruiting USA 0
NCT02656303 Phase II Ublituximab + Umbralisib An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 Enrolling by invitation USA 3
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Terminated 0
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Recruiting USA 0
NCT02717611 Phase II Acalabrutinib A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy Active, not recruiting USA 5
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02733042 Phase Ib/II Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting USA 6
NCT02742090 Phase II Umbralisib Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy Completed USA 0
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn 0
NCT02756611 Phase III Venetoclax A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor (VENICE I) Active, not recruiting USA | CAN 19
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02801578 Phase I Ibrutinib A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) Completed USA 0
NCT02846623 Phase II Atezolizumab + Obinutuzumab + Venetoclax Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Recruiting USA 0
NCT02860676 Phase I Cirmtuzumab Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 Completed USA 0
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Active, not recruiting USA 0
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Completed USA 0
NCT02912754 Phase Ib/II Ibrutinib Ibrutinib + Ruxolitinib Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients Unknown status CAN 0
NCT02914327 Phase I Ibrutinib + SNX-5422 Safety and Activity of SNX-5422 Plus Ibrutinib in CLL Withdrawn USA 0
NCT02948283 Phase 0 Metformin + Ritonavir Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Completed USA 0
NCT02970318 Phase III Bendamustine + Idelalisib + Rituximab Acalabrutinib A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Active, not recruiting USA | CAN 23
NCT02973399 Phase I Ibrutinib + SNX-5422 Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL Terminated USA 0
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03037645 Phase Ib/II Vecabrutinib Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Terminated USA 0
NCT03041636 Phase II Ruxolitinib Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Completed USA 0
NCT03045328 Phase Ib/II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Completed USA 0
NCT03056339 Phase Ib/II Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Active, not recruiting USA 0
NCT03069469 Phase I DCC-3014 Study of DCC-3014 in Patients With Advanced Malignancies Recruiting USA | CAN 7
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03128879 Phase II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting USA 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03153202 Phase Ib/II Ibrutinib + Pembrolizumab Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Recruiting USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting USA 0
NCT03207256 Phase II Ublituximab + Umbralisib Umbralisib Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials Enrolling by invitation USA 0
NCT03207555 Phase II Ibrutinib Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) Recruiting USA 0
NCT03219450 Phase I NeoVax Cyclophosphamide + NeoVax A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naive, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia. Recruiting USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed 3
NCT03265717 Phase II INVAC-1 DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia Terminated USA 0
NCT03283137 Phase I Pembrolizumab + Umbralisib Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Recruiting USA 0
NCT03331198 Phase Ib/II Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Recruiting USA 0
NCT03336333 Phase III Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) Recruiting USA 13
NCT03370185 Phase II Duvelisib Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Withdrawn USA 0
NCT03379051 Phase Ib/II Ublituximab + Umbralisib + Venetoclax Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Recruiting USA 0
NCT03400176 Phase I Ibrutinib + VAY736 VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib Recruiting USA 0
NCT03406156 Phase III Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Active, not recruiting USA 0
NCT03422393 Phase I Ibrutinib + Venetoclax Venetoclax Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib Active, not recruiting USA 0
NCT03447808 Phase I Daratumumab + Ibrutinib Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Recruiting USA 0
NCT03454165 Phase I BNC105P + Ibrutinib A Study of BNC105P Combined With Ibrutinib Active, not recruiting USA 0
NCT03462719 Phase III Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Active, not recruiting USA | CAN 12
NCT03467867 Phase II Hyaluronidase + Rituximab + Venetoclax Rituximab + Venetoclax A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL Recruiting USA 0
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03513562 Phase II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations Recruiting USA 0
NCT03514017 Phase II Ibrutinib + Pembrolizumab Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia Recruiting USA 0
NCT03534323 Phase Ib/II Duvelisib + Venetoclax Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL Recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA 1
NCT03579888 Phase I CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine CD19-Specific T Cells Post AlloSCT Terminated USA 0
NCT03580928 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) Recruiting USA 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03609593 Phase II Rituximab Bendamustine + Rituximab Venetoclax Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Recruiting USA 0
NCT03624036 Phase Ib/II Cyclophosphamide + Fludarabine axicabtagene ciloleucel Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) Active, not recruiting USA 1
NCT03639324 Phase I Idelalisib + Rituximab + Venetoclax Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL) Withdrawn 0
NCT03701282 Phase III Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 1
NCT03734198 Phase II Daratumumab + Ibrutinib Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) Recruiting 1
NCT03737981 Phase III Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Recruiting USA 0
NCT03739554 Phase I CYC065 + Venetoclax CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL Unknown status USA 0
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting USA 9
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Recruiting 4
NCT03759184 Phase I Obinutuzumab + rhIL-15 Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Active, not recruiting USA 0
NCT03766763 Phase II Venetoclax Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Recruiting 1
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Recruiting USA 6
NCT03788291 Phase II Acalabrutinib + Rituximab Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Recruiting USA 0
NCT03801525 Phase II Ublituximab + Umbralisib + Venetoclax Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL (ULTRA-V) Recruiting USA 0
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03824483 Phase II Obinutuzumab + Venetoclax + Zanubrutinib Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Recruiting USA 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting USA 0
NCT03836261 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL Recruiting USA | CAN 29
NCT03893682 Phase I CG-806 A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Recruiting USA 0
NCT03900598 Phase I JNJ-67856633 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA 11
NCT03943342 Phase II Ibrutinib Ibrutinib + Venetoclax Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Withdrawn 0
NCT03960840 Phase I Ibrutinib + YTB323 YTB323 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Recruiting USA 5
NCT03986034 Phase II Venetoclax Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting USA 0
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04008706 Phase III Acalabrutinib Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) Active, not recruiting USA | CAN 15
NCT04010968 Phase II Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC) Active, not recruiting 1
NCT04016805 Phase II Ublituximab + Umbralisib + Venetoclax Ibrutinib + Ublituximab + Umbralisib Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax Recruiting USA 0
NCT04029038 Phase Ib/II CD19/CD22 CAR T cells Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Not yet recruiting USA 0
NCT04043845 Phase I Ibrutinib + LY3214996 ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Withdrawn 0
NCT04116437 Phase II Zanubrutinib A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib Recruiting USA 0
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Recruiting USA 0
NCT04149821 Phase II Ublituximab + Umbralisib Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy Recruiting USA 0
NCT04155840 Phase II Bendamustine + Copanlisib + Rituximab Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Terminated USA 0
NCT04163718 Phase II Umbralisib TGR-1202 (Umbralisib) in Treatment Naive Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting USA 0
NCT04169737 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT04178798 Phase III Acalabrutinib Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia Recruiting 1
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT04209621 Phase II Duvelisib + Ibrutinib Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed USA 0
NCT04210219 Phase I JNJ-64264681 A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Recruiting USA 6
NCT04230304 Phase II Daratumumab + Ibrutinib Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Recruiting USA 0
NCT04240704 Phase I JBH492 Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) Recruiting USA 7
NCT04245722 Phase I Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies Recruiting USA 0
NCT04269902 Phase III Obinutuzumab + Venetoclax Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study Recruiting USA 0
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04285567 Phase III Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) Recruiting USA 4
NCT04305444 Phase II DTRMWXHS-12 + Everolimus + Pomalidomide Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Recruiting USA 0
NCT04358458 Phase Ib/II GEN3009 First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Recruiting USA 6
NCT04419389 Phase Ib/II APR-246 + Ibrutinib APR-246 + Rituximab + Venetoclax APR-246 + Ibrutinib + Rituximab + Venetoclax APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R) Active, not recruiting USA 0
NCT04419519 Phase II Venetoclax Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Recruiting USA 0
NCT04447768 Phase II Obinutuzumab + Venetoclax The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Recruiting USA 0
NCT04502394 Phase Ib/II Acalabrutinib + KRT-232 Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL Recruiting USA 4
NCT04509700 Phase II Parsaclisib Itacitinib + Parsaclisib Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Recruiting USA 4
NCT04512105 Phase I Azacitidine + Pitavastatin + Venetoclax Decitabine + Pitavastatin + Venetoclax Pitavastatin + Venetoclax Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia Recruiting USA 0
NCT04515238 Phase II Bendamustine + Obinutuzumab + Venetoclax + Zanubrutinib Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG) Recruiting 1
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA 7
NCT04560322 Phase II Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL Recruiting USA 0
NCT04599634 Phase I Hu5F9-G4 + Obinutuzumab + Venetoclax Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Not yet recruiting USA 0
NCT04608318 Phase III Ibrutinib Ibrutinib + Venetoclax Obinutuzumab + Venetoclax Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17) Recruiting 1
NCT04623541 Phase Ib/II Epcoritamab Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting USA 4
NCT04624633 Phase II Acalabrutinib + Ublituximab + Umbralisib AU2 In Relapsed and Untreated CLL Recruiting USA 0
NCT04657094 Phase II Acalabrutinib Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04657224 Phase I JNJ-64264681 + JNJ-67856633 A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Recruiting USA 11
NCT04660045 Phase II Acalabrutinib Early Intervention With Acalabrutinib in Patients With High Risk CLL Not yet recruiting USA 0
NCT04679012 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Not yet recruiting USA 0
NCT04685915 Phase II Copanlisib + Ibrutinib Copanlisib Plus Ibrutinib in R/R CLL Recruiting USA 0
NCT04722172 Phase II Acalabrutinib + Obinutuzumab A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL Recruiting USA 0
NCT04781855 Phase I Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Not yet recruiting USA 0
NCT04806035 Phase I TG-1801 + Ublituximab TG-1801 Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA 0
NCT04876092 Phase I Ibrutinib + JNJ-67856633 A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in B-cell NHL and CLL Recruiting USA 10
NCT04883749 Phase II Acalabrutinib Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail) Recruiting 2
NCT04895436 Phase II Obinutuzumab + Venetoclax Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) Not yet recruiting USA 3
NCT05091424 Phase I BTCT4465A + Tocilizumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Recruiting 1